Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.66 |
| ▸ | CES2 | O00748 | 1/20 | 0.65 |
| ▸ | CES1 | P23141 | 1/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.56 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.56 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30301359 | 0.98 | PARP1 (0.64) | PARP1CES2CES1CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL1181823 | 0.98 | PARP1 (0.64) | PARP1CES2CES1CHRM2CHRM1 | |
| SCHEMBL11248287 | 0.85 | CES2 (0.69) | PARP1CES2CES1CHRM2CHRM1 | |
| SCHEMBL30758862 | 0.85 | CES2 (0.69) | PARP1CES2CES1CHRM2CHRM1 | |
| SCHEMBL2278242 | 0.84 | CES2 (0.62) | PARP1CES2CES1CHRM2CHRM1 | |
| SCHEMBL1305114 | 0.84 | CES2 (0.67) | PARP1CES2CES1CHRM2CHRM1 | |
| SCHEMBL733307 | 0.84 | CES2 (0.67) | PARP1CES2CES1CHRM2CHRM1 | |
| SCHEMBL29588852 | 0.84 | CES2 (0.67) | PARP1CES2CES1CHRM2CHRM1 | |
| SCHEMBL9559962 | 0.83 | HPGD (0.54) | NPC1RAB9APOLBSMN1; SMN2MEN1 | |
| SCHEMBL3846484 | 0.83 | PARP1 (0.67) | PARP1CES2CES1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| US-20230150924-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | CELLGENTEK CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-20230150924-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | CELLGENTEK CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| CN-111646973-B | Polysubstituted quinazoline derivative and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-07-19 | — | — | CN | disclosed |
| EP-4019495-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | Cellgentek Co., Ltd (KR) | 2022-06-29 | — | — | EP | disclosed |
| US-11345678-B2 | Benzopyrazole compound used as RHO kinase inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2022-05-31 | — | — | US | disclosed |
| CN-109280028-B | Quinoline compound and application thereof in DPP-4 enzyme inhibitor | 上海医药工业研究院 | 2022-03-25 | — | — | CN | disclosed |
| US-20210371393-A1 | BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2021-12-02 | — | — | US | disclosed |
| CN-108558756-B | 2-aryl-2, 3-dihydro-4 (1H) -quinolinone semicarbazone compound and application thereof | 沈阳药科大学 | 2021-08-03 | — | — | CN | disclosed |
| US-20210093624-A1 | Chemical Synthesis of Clopidogrel Active Metabolites and Disulfide Conjugate Prodrugs | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-04-01 | — | — | US | disclosed |
| US-5166170-A | 2-(AMINOARYL) INDOLES AND INDOLINES AS TOPICAL ANTIINFLAMMATORY AGENTS FOR THE TREATMENT OF SKIN DISORDERS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-11-24 | — | — | US | disclosed |
| EP-0471358-A1 | Fluoroethylcamptothecin derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1992-02-19 | — | — | EP | disclosed |
| EP-0406734-A2 | 2-(Aminoaryl)indoles and indolines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-01-09 | — | — | EP | disclosed |
| EP-0107398-B1 | ORTHO SUBSTITUTED DIHYDROXY-2(1H)QUINAZOLINONE-1-ALKANOIC ACIDS | ORTHO PHARMA CORP (US) | 1988-06-08 | — | — | EP | disclosed |
| US-4666499-A | Herbicidal 2 methyl-4-phosphinylcinnolinium hydroxide inner salts | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-05-19 | — | — | US | disclosed |
| US-4631283-A | RENAL VASODILATORS, CARDIOVASCULAR AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1986-12-23 | — | — | US | disclosed |
| US-4620000-A | Method for preparing 4-hydroxycinnolines in a pH controlled system | SHELL OIL COMPANY (US) | 1986-10-28 | — | — | US | disclosed |
| US-4490374-A | CARDIOVASCULAR AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1984-12-25 | — | — | US | disclosed |
| EP-0107398-A1 | Ortho substituted dihydroxy-2(1H)quinazolinone-1-alkanoic acids | ORTHO PHARMACEUTICAL CORPORATION (US) | 1984-05-02 | — | — | EP | disclosed |
| US-3987047-A | ANORETICS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345678-B2 | Benzopyrazole compound used as RHO kinase inhibitor | ROCK1, ROCK2, CIT | PARP1 1380/4885CES2 4205/4885CES1 1510/4885 |
| US-20230150924-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | KNTC1, MED1, LEF1 | PARP1 1772/4885CES2 4819/4885CES1 810/4885 |
| US-20210093624-A1 | Chemical Synthesis of Clopidogrel Active Metabolites and Disulfide Conjugate Prodrugs | CYP2B6, MPST, POR | PARP1 709/4885CES2 205/4885CES1 112/4885 |
| US-20210371393-A1 | BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR | ROCK1, ROCK2, CIT | PARP1 1380/4885CES2 4205/4885CES1 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.